文献速递瓣膜病与结构性心脏病

REPRISE III 试验:Lotus 与 CoreValve 经导管主动脉瓣的血流动力学与超声心动图比较

Hemodynamic and Echocardiographic Comparison of the Lotus and CoreValve Transcatheter Aortic Valves in Patients With High and Extreme Surgical Risk: An Analysis From the REPRISE III Randomized Controlled Trial.
PubMed 文献 · Circulation · 2018-03-12

REPRISE III 是一项多中心随机试验,纳入 912 例极高/高危主动脉瓣狭窄患者,按 2:1 随机接受 Lotus 或 CoreValve 经导管主动脉瓣置换。CoreValve 出院时平均跨瓣压差更低、瓣口面积和 Doppler 速度指数更大,但差异随随访至 1 年缩小;Lotus 的中重度瓣周漏发生率持续更低。两组全因死亡、致残性卒中及中重度瓣周漏复合终点无差异。

要点

  • CoreValve 出院时跨瓣压差更低、瓣口面积更大,但差异至 1 年随访缩小。
  • Lotus 的中重度瓣周漏发生率持续低于 CoreValve。
  • 两组全因死亡及死亡、致残性卒中、中重度瓣周漏复合终点无差异。

核心结论

  • Lotus 的中重度瓣周漏发生率显著低于 CoreValve,但瓣口面积更小、跨瓣压差更高。
  • 上述血流动力学差异未转化为 1 年随访时死亡、致残性卒中及中重度瓣周漏复合终点或生活质量的临床差异。

研究设计与样本

  • REPRISE III 为多中心随机对照试验,在 55 个中心纳入极高危和高危主动脉瓣狭窄患者。
  • 共 912 例患者按 2:1 随机分配至 Lotus 组(607 例)或 CoreValve 组(305 例)。
  • 患者中位年龄 84 岁,女性占 51%,STS 评分为 6.8±4.1。
  • 所有经胸超声心动图 Doppler 检查按标准方案于植入后至 12 个月获取,并由核心实验室分析。

主要发现

  • 出院时 CoreValve 较 Lotus 显示更低的跨瓣压差、更大的主动脉瓣面积和 Doppler 速度指数,差异在后续随访至 1 年时减小(所有 P<0.01)。
  • Lotus 的瓣周漏发生率更低,且该差异随时间持续(P<0.05)。
  • 按瓣膜尺寸分组(小、中、大)比较时,结果相似。
  • 全因死亡率在两种瓣膜的三个尺寸组中均无差异。
  • 全人群中将正常跨瓣压差(<20 mm Hg,n=780)与异常跨瓣压差(>20 mm Hg,n=48)患者比较,全因死亡率无差异;分别评估每种瓣膜时亦无显著差异。

关键数值与推荐

  • 跨瓣压差分组阈值:正常<20 mm Hg(n=780),异常>20 mm Hg(n=48)。
  • 主动脉瓣面积分组阈值:>1.1 cm²与<1.1 cm²。
  • Doppler 速度指数分组阈值:>0.35 与<0.35。
  • 瓣周漏评估采用多参数方法,Lotus 中重度瓣周漏发生率更低(P<0.05)。

临床怎么用

  • 在高危/极高危主动脉瓣狭窄患者选择瓣膜时,Lotus 可能降低中重度瓣周漏风险,而 CoreValve 提供更低的跨瓣压差和更大的瓣口面积。
  • 两组 1 年临床复合终点无差异,提示上述血流动力学差异未转化为硬终点获益。
  • 跨瓣压差、瓣口面积及 Doppler 速度指数的组间差异随时间缩小,随访评估需考虑时间因素。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Comparative echocardiographic data on transcatheter aortic valve replacement systems from randomized trials are limited. The REPRISE III trial (Repositionable Percutaneous Replacement of Stenotic Aortic Valve through Implantation of Lotus Valve System - Randomized Clinical Evaluation) is a multicenter, randomized comparison of a mechanically expanded (Lotus) versus self-expanding (CoreValve) transcatheter aortic valve replacement device. This analysis rigorously assesses Doppler-derived valve hemodynamics and the impact on outcomes at 1 year in patients with extreme/high surgical risk treated with Lotus and CoreValve from REPRISE III. METHODS: REPRISE III includes patients with extreme- and high-risk aortic stenosis. Patients were enrolled at 55 centers. All transthoracic echocardiograms with Doppler were obtained following a standard protocol up to 12 months postimplant and analyzed by a core laboratory. Valve size, mean gradient, aortic valve area, and Doppler velocity index and their impact on clinical outcomes are reported. Additional parameters including paravalvular leak were evaluated using a multiparametric approach. RESULTS: A total of 912 patients were randomly assigned (2:1 ratio; 607 Lotus:305 CoreValve). Median age was 84 years, 51% of the patients were women, and the Society of Thoracic Surgeons score was 6.8±4.1. CoreValve demonstrated lower gradients and larger aortic valve area and Doppler velocity index than Lotus at discharge; the difference decreased in subsequent follow-up up to a year (all P<0.01). Lotus had lower rates of paravalvular leak that persisted over time (P<0.05). Similar outcomes were seen when comparing each valve type by size group (small, medium, large). The hemodynamic differences between valves did not translate into worse clinical outcomes. All-cause mortality was not different between the 2 groups in any of the 3 valve sizes. When comparing patients with normal valve gradients (<20 mm Hg, n=780) with those with abnormal gradients (>20 mm Hg, n=48) in the entire patient population, all-cause mortality was not different. This was also not significant when evaluating each valve type separately. Similarly, there were no differences for aortic valve area >1.1 cm2 or <1.1 cm2 and for Doppler velocity index >0.35 or <0.35 (all P=not significant). CONCLUSIONS: Lotus had significantly greater freedom from moderate or severe paravalvular leak and smaller valve area and higher gradients than CoreValve. The hemodynamic differences were not associated with any clinical differences in the composite end point of mortality, disabling stroke, and moderate paravalvular leak or with quality of life at 1 year of follow-up. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02202434.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Asch FM, Vannan MA, Singh S, et al. Hemodynamic and Echocardiographic Comparison of the Lotus and CoreValve Transcatheter Aortic Valves in Patients With High and Extreme Surgical Risk: An Analysis From the REPRISE III Randomized Controlled Trial. Circulation. 2018. PMID: 29530883. doi:10.1161/CIRCULATIONAHA.118.034129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。